Tesaro's Path To A Billion-Dollar Blockbuster Begins With Pricing

Tesaro (NASDAQ:TSRO) won FDA approval of its new cancer drug Zejula in March, and this week, management reported that Zejula is now available at a dose of 200 mg per day with a list price of $9,833 per month. The price is in the ballpark of existing drugs in Zejula's class, and given Zejula has the broadest addressable patient population, the market potential for this drug is big.

Back to news